Consequently, the first human clinical trials of dasatinib plus quercetin (D+Q) treatment for patients with idiopathic pulmonary fibrosis (IPF) and diabetic kidney disease (DKD) showed preliminary evidence of improved physical function measures, decreased adipose tissue senescent cell burden, and decreased circulating SASP factors like IL-1α and IL-6 [50,97]. The gene discussed is IL1A; the disease is idiopathic pulmonary fibrosis.